The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Intellia Therapeutics Inc’s stock clocked out at $10.01, down -5.12% from its previous closing price of $10.55. In other words, the price has decreased by -$5.12 from its previous closing price. On the day, 3.14 million shares were traded. NTLA stock price reached its highest trading level at $10.67 during the session, while it also had its lowest trading level at $9.99.
Ratios:
To gain a deeper understanding of NTLA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.73 and its Current Ratio is at 6.73. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on January 27, 2025, Downgraded its rating to Equal-Weight and sets its target price to $11 from $56 previously.
On February 23, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $136 to $32.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 03 ’25 when Dube Michael P sold 1,372 shares for $12.18 per share. The transaction valued at 16,711 led to the insider holds 45,640 shares of the business.
BASTA JAMES sold 7,074 shares of NTLA for $86,161 on Jan 03 ’25. The EVP, General Counsel now owns 74,497 shares after completing the transaction at $12.18 per share. On Jan 03 ’25, another insider, Lebwohl David, who serves as the EVP, Chief Medical Officer of the company, sold 9,557 shares for $12.18 each. As a result, the insider received 116,404 and left with 87,666 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 1019508544 and an Enterprise Value of 463013216. For the stock, the TTM Price-to-Sale (P/S) ratio is 23.66 while its Price-to-Book (P/B) ratio in mrq is 1.06. Its current Enterprise Value per Revenue stands at 10.746 whereas that against EBITDA is -0.878.
Stock Price History:
The Beta on a monthly basis for NTLA is 1.80, which has changed by -0.5570949 over the last 52 weeks, in comparison to a change of 0.25219524 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $34.87, while it has fallen to a 52-week low of $9.25. The 50-Day Moving Average of the stock is -21.35%, while the 200-Day Moving Average is calculated to be -49.38%.
Shares Statistics:
It appears that NTLA traded 2.84M shares on average per day over the past three months and 3320950 shares per day over the past ten days. A total of 101.80M shares are outstanding, with a floating share count of 99.72M. Insiders hold about 2.09% of the company’s shares, while institutions hold 92.45% stake in the company. Shares short for NTLA as of 1736899200 were 24060839 with a Short Ratio of 8.48, compared to 1734048000 on 19807004. Therefore, it implies a Short% of Shares Outstanding of 24060839 and a Short% of Float of 26.91.
